Alnylam Pharmaceuticals 주식 (NASDAQ: ALNY)

에 대한 최신 뉴스 Alnylam Pharmaceuticals (NASDAQ:ALNY) 주식

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Biotech

Equities

Large Cap

Sector ETFs

Broad U.S. Equity ETFs

Health Care

Tech

ETFs

ADBE

ALNY

AVGO

COPX

CRWD

OLED

ORCL

QRVO

iShares FTSE NAREIT Residential PLUS Capped Index Fund

SCLX

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

6월은 섹터 및 산업 성과의 상당한 격차에도 불구하고 SPDR S&amp;P 500 ETF Trust(NYSE:SPY)가 추적하는 S&amp;P 500이 3.2% 상승하는 등 주식 시장에서 높은 평가를 받으며 마감되었다.

6월 상위 성과 업종 ETF: 소프트웨어는 수익을 선도, 칩 메이커들은 가장 많은 자금 유치

News

Movers

CVNA

FTAI

MSTR

RDDT

RIVN

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 리비안 오토모티브(NASDAQ:RIVN)는 회사가 생산량을 단순화하고 비용을 절감했으며 폭스바겐과의 합작 투자 계획을 발표했다는 보도가 나온 후 지난주 주가가 30.04% 급등했다. 

리비안과 카바나는 지난주 최고의 성과를 보인 10대 대형주 중 일부 (6월 23일-6월 29일)

Markets

AFRM

NVDA

TSLA

월요일 미국 주요 지수들은 혼조세를 보였다. 다우존스 산업평균지수는 0.7% 가까이 오른 39,411.21에 마감했고, S&amp;P 500 지수는 0.3% 하락한 5,447.87에 마감했다. 나스닥 지수는 1.1% 가까이 하락한 17,496.82로 마감했다. 이들은 하루 동안 소매 거래자와 투자자들의 주목을 받은 주요 종목들이다:

월요일 주목받은 주식 5종목: 엔비디아, 어펌 홀딩스, 카니발, 앨라일람 파마, 테슬라

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 10 years by 4.95% on an annualized basis producing an average annual return of 15.84%. Currently, Alnylam Pharmaceuticals has a market capitalization of $31.40 billion. 
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 10 years ago, it would be worth $404.56 today based on a price of $248.25 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1720031418_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth This Much Today

JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Neutral and raises the price target from $160 to $248.

Price Target

Analyst Ratings

JP Morgan Maintains Neutral on Alnylam Pharmaceuticals, Raises Price Target to $248

June closed on a high note for the stock market, with the S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), gaining 3.2%, despite significant disparities in <a href="https://www.benzinga.com/etfs">sector and industry performances.</a>
The technology sector, as tracked by the Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>), led the 11 S&amp;P 500 sectors in performance last month, surging 7.7% and achieving its strongest monthly gain this year. 
In stark contrast, utilities lagged, with the Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) dropping 6.3%, marking the worst month since September 2023.
<h3 class="wp-block-heading">Top Performing Industry ETFs In June</h3>
The iShares Expanded Tech-Software Sector ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGV#NYSE">IGV</a>) rallied 11.3% last month, topping the rankings among industry ETFs. 
Hot on its heels was the VanEck Semiconductor ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NYSE">SMH</a>), which climbed 8.4%, showcasing strong momentum in the semiconductor sector. 
Since hitting its low in October 2023, the VanEck Semiconductor ETF has rallied by an astounding 87%, and over 200% since October 2022, reflecting the spectacular growth in AI-driven stocks.
Securing the third spot in terms of monthly performance, the SPDR S&amp;P Biotech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XBI#NYSE">XBI</a>) gained 4%. 
Within the software sector, standout performers included Adobe Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>), which surged by 24.9%, CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a 22.1% increase, and Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>), up by 20%.
Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) led chipmakers with a 21% rise. Universal Display Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLED#NYSE">OLED</a>) followed closely with a 19.7% increase, and Qorvo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) posted an 18% gain. 
Among chipmakers, Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), Universal Display Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLED#NYSE">OLED</a>) and Qorvo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) led gains, with performances of 21%, 19.7% and 18%, respectively.
In the biotech arena, Scilex Holding Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCLX#NASDAQ">SCLX</a>) experienced a 78.8% spike, making it the top industry gainer. Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) surged by 63.7%, while Avidity Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) saw a robust 52% increase.
<h3 class="wp-block-heading">Top Performing Industry ETFs By Inflows In June</h3>
Examining fund flows, the VanEck Semiconductor ETF has emerged as a top choice for investors, attracting over $1 billion according to Tradingview data, and achieving its ninth consecutive month of inflows. Year-to-date the fund has registered $4.60 billion in net inflows.
The iShares Expanded Tech-Software Sector ETF pulled in approximately $480 million in June, breaking a six-month streak of outflows and registering its highest monthly inflows since September 2022. Yet, its year-to-date net flows are still negative, down by $1.15 billion. 
The iShares Biotechnology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBB#NYSE">IBB</a>) collected $148 million in inflows last month, reflecting strong investor interest. Another industry witnessing robust inflows was represented by the Global X Copper Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COPX#NYSE">COPX</a>), which attracted about $130 million.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39577080/manufacturing-contracts-more-than-expected-in-june-putting-pressure-on-profitabilit">Manufacturing Contracts More Than Expected In June, &#8216;Putting Pressure On Profitability&#8217;: Yields Rise, Stocks Fall</a></li>
</ul>
Photo: Shutterstock

Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRNX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$50.00</td>
<td>$660.0K</td>
<td>236</td>
<td>2.8K</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/05/24</td>
<td>$22.00</td>
<td>$88.7K</td>
<td>856</td>
<td>1.6K</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/12/24</td>
<td>$247.50</td>
<td>$80.6K</td>
<td>1.0K</td>
<td>622</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/12/24</td>
<td>$485.00</td>
<td>$29.7K</td>
<td>56</td>
<td>259</td>
</tr>
<tr>
<td>ALNY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/19/24</td>
<td>$185.00</td>
<td>$71.4K</td>
<td>1.0K</td>
<td>150</td>
</tr>
<tr>
<td>IQV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$210.00</td>
<td>$33.1K</td>
<td>2.5K</td>
<td>35</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$41.00</td>
<td>$33.6K</td>
<td>3.6K</td>
<td>32</td>
</tr>
<tr>
<td>SAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$12.50</td>
<td>$1.5 million</td>
<td>839</td>
<td>28</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$900.00</td>
<td>$30.3K</td>
<td>1.5K</td>
<td>9</td>
</tr>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$440.00</td>
<td>$29.6K</td>
<td>50</td>
<td>0</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For CRNX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNX#NASDAQ">CRNX</a>), we notice a call option trade that happens to be bearish, expiring in 81 day(s) on September 20, 2024. This event was a transfer of 2200 contract(s) at a $50.00 strike. The total cost received by the writing party (or parties) was $660.0K, with a price of $300.0 per contract. There were 236 open contracts at this strike prior to today, and today 2880 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option trade with bearish sentiment. It expires in 4 day(s) on July 5, 2024. Parties traded 4438 contract(s) at a $22.00 strike. The total cost received by the writing party (or parties) was $88.7K, with a price of $20.0 per contract. There were 856 open contracts at this strike prior to today, and today 1684 contract(s) were bought and sold. 
• Regarding DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we observe a put option sweep with neutral sentiment. It expires in 11 day(s) on July 12, 2024. Parties traded 152 contract(s) at a $247.50 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $80.6K, with a price of $530.0 per contract. There were 1019 open contracts at this strike prior to today, and today 622 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option trade that happens to be bearish, expiring in 11 day(s) on July 12, 2024. This event was a transfer of 99 contract(s) at a $485.00 strike. The total cost received by the writing party (or parties) was $29.7K, with a price of $300.0 per contract. There were 56 open contracts at this strike prior to today, and today 259 contract(s) were bought and sold. 
• For ALNY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>), we notice a call option trade that happens to be neutral, expiring in 18 day(s) on July 19, 2024. This event was a transfer of 12 contract(s) at a $185.00 strike. The total cost received by the writing party (or parties) was $71.4K, with a price of $5950.0 per contract. There were 1086 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• For IQV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>), we notice a put option sweep that happens to be bullish, expiring in 18 day(s) on July 19, 2024. This event was a transfer of 77 contract(s) at a $210.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $33.1K, with a price of $430.0 per contract. There were 2558 open contracts at this strike prior to today, and today 35 contract(s) were bought and sold. 
• For BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we notice a put option sweep that happens to be bullish, expiring in 46 day(s) on August 16, 2024. This event was a transfer of 200 contract(s) at a $41.00 strike. This particular put needed to be split into 29 different trades to become filled. The total cost received by the writing party (or parties) was $33.6K, with a price of $168.0 per contract. There were 3612 open contracts at this strike prior to today, and today 32 contract(s) were bought and sold. 
• Regarding SAVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>), we observe a call option trade with bearish sentiment. It expires in 564 day(s) on January 16, 2026. Parties traded 1999 contract(s) at a $12.50 strike. The total cost received by the writing party (or parties) was $1.5 million, with a price of $755.0 per contract. There were 839 open contracts at this strike prior to today, and today 28 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be neutral, expiring in 200 day(s) on January 17, 2025. This event was a transfer of 3 contract(s) at a $900.00 strike. The total cost received by the writing party (or parties) was $30.3K, with a price of $10126.0 per contract. There were 1599 open contracts at this strike prior to today, and today 9 contract(s) were bought and sold. 
• For ISRG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), we notice a put option trade that happens to be bullish, expiring in 200 day(s) on January 17, 2025. This event was a transfer of 9 contract(s) at a $440.00 strike. The total cost received by the writing party (or parties) was $29.6K, with a price of $3292.0 per contract. There were 50 open contracts at this strike prior to today, and today 0 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

CRNX

Hims & Hers Health, Inc. Class A Common Stock

HIMS

ISRG

SAVA

10 Health Care Stocks With Whale Alerts In Today's Session

Cantor Fitzgerald analyst Olivia Brayer reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Neutral and maintains $150 price target.

Reiteration

Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $150 Price Target

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) shares surged 30.04%  in the last week following a report suggesting the company has simplified its output, cut costs and announced plans for a<a href="https://www.benzinga.com//node/39497161" target="_blank" rel="noreferrer noopener"> joint venture with Volkswagen</a>.</li>
<li>Carnival Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUK#NYSE">CUK</a>) stock gained 17.78% on continued strength following <a href="https://www.benzinga.com//node/39481992" target="_blank" rel="noreferrer noopener">better-than-expected&nbsp;Q2&nbsp;earnings</a>.</li>
<li>FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) stock soared 17.51% in the last week&nbsp;on better-than-expected&nbsp;Q4&nbsp;financial results and guidance. Also, the company announced it expects to buy back&nbsp;$2.5 billion&nbsp;<a href="https://www.benzinga.com//node/39504381" target="_blank" rel="noreferrer noopener">worth of stock in FY25</a>. Several analysts raised the <a href="https://www.benzinga.com//node/39509568" target="_blank" rel="noreferrer noopener">price forecasts on the stock</a>.</li>
<li>Samsara Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>) stock advanced 16.37% after RBC Capital reiterated an Outperform rating and maintained its<a href="https://www.benzinga.com/quote/iot/analyst-ratings" target="_blank" rel="noreferrer noopener"> price target of&nbsp;$47</a>.</li>
<li>Suzano S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUZ#NYSE">SUZ</a>) shares rose 12.24% after it <a href="https://www.benzinga.com//node/39519611" target="_blank" rel="noreferrer noopener">dropped the acquisition</a> pursuit of International Paper Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IP#NYSE">IP</a>).</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) shares increased 11.93% after updating&nbsp;on its operating plan and capital structure at the William Blair 44th Annual Growth Stock <a href="https://www.benzinga.com//node/39509401" target="_blank" rel="noreferrer noopener">Conference in early June</a>.</li>
<li>FTAI Aviation Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) stock gained 11.55% in the last week.</li>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) shares surged 11.08% after the company announced a policy update to block <a href="https://www.benzinga.com//node/39494776" target="_blank" rel="noreferrer noopener">automated website scraping</a>.</li>
<li>Mongodb Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) stock gained 10.57% in the last week.</li>
<li>Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) shares rose 10.82% amid possible continued strength after the company announced topline results from its HELIOS-B Phase 3 study of vutrisiran. Also, multiple analyst firms raised their <a href="https://www.benzinga.com/quote/alny/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecasts on the stock</a>.</li>
</ol>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/06/39565694/moderna-and-walgreens-boots-alliance-were-among-the-10-biggest-large-cap-losers-last-week-june-23-">Moderna And Walgreens Boots Alliance Were Among The 10 Biggest Large Cap Losers Last Week (June 23 &#8211; June 29): Are These In Your Portfolio?</a></li>
</ul>
Photo Courtesy of Rivian

Rivian Automotive And Carvana Were Among The 10 Biggest Large Cap Gainers Last Week (June 23-June 29): Are These In Your Portfolio?

UBS analyst Eliana Merle maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $253 to $288.

UBS Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $288

Alnylam Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NYSE">ALNY</a>) short percent of float has fallen 14.16% since its last report. The company recently reported that it has 2.13 million shares sold short, which is 1.94% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.52 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Alnylam Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1719510309_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Alnylam Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Alnylam Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Alnylam Pharmaceuticals's peer group average for short interest as a percentage of float is 6.35%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Alnylam Pharmaceuticals's Recent Short Interest

RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Outperform and raises the price target from $250 to $265.

RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $265

Stifel analyst Paul Matteis maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $215 to $295.

Stifel Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $295

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$28.00</td>
<td>$74.9K</td>
<td>29.5K</td>
<td>5.7K</td>
</tr>
<tr>
<td>ZTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$170.00</td>
<td>$39.0K</td>
<td>849</td>
<td>809</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/12/24</td>
<td>$115.00</td>
<td>$33.6K</td>
<td>47</td>
<td>547</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$880.00</td>
<td>$69.0K</td>
<td>1.0K</td>
<td>129</td>
</tr>
<tr>
<td>RMD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$180.00</td>
<td>$29.0K</td>
<td>27</td>
<td>41</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$300.00</td>
<td>$68.3K</td>
<td>33</td>
<td>32</td>
</tr>
<tr>
<td>RXRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$8.00</td>
<td>$31.0K</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$120.00</td>
<td>$52.0K</td>
<td>1.1K</td>
<td>7</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$240.00</td>
<td>$514.0K</td>
<td>18</td>
<td>2</td>
</tr>
<tr>
<td>STAA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$30.00</td>
<td>$32.6K</td>
<td>33</td>
<td>0</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option sweep that happens to be bearish, expiring in 23 day(s) on July 19, 2024. This event was a transfer of 2203 contract(s) at a $28.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $74.9K, with a price of $34.0 per contract. There were 29538 open contracts at this strike prior to today, and today 5759 contract(s) were bought and sold. 
• For ZTS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), we notice a call option sweep that happens to be bearish, expiring in 23 day(s) on July 19, 2024. This event was a transfer of 100 contract(s) at a $170.00 strike. This particular call needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $39.0K, with a price of $390.0 per contract. There were 849 open contracts at this strike prior to today, and today 809 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a put option sweep with bearish sentiment. It expires in 16 day(s) on July 12, 2024. Parties traded 200 contract(s) at a $115.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $33.6K, with a price of $168.0 per contract. There were 47 open contracts at this strike prior to today, and today 547 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option sweep that happens to be bearish, expiring in 23 day(s) on July 19, 2024. This event was a transfer of 20 contract(s) at a $880.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $69.0K, with a price of $3453.0 per contract. There were 1029 open contracts at this strike prior to today, and today 129 contract(s) were bought and sold. 
• Regarding RMD (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>), we observe a put option trade with bearish sentiment. It expires in 177 day(s) on December 20, 2024. Parties traded 24 contract(s) at a $180.00 strike. The total cost received by the writing party (or parties) was $29.0K, with a price of $1210.0 per contract. There were 27 open contracts at this strike prior to today, and today 41 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bullish, expiring in 569 day(s) on January 16, 2026. This event was a transfer of 47 contract(s) at a $300.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $68.3K, with a price of $1455.0 per contract. There were 33 open contracts at this strike prior to today, and today 32 contract(s) were bought and sold. 
• Regarding RXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), we observe a call option trade with bullish sentiment. It expires in 51 day(s) on August 16, 2024. Parties traded 200 contract(s) at a $8.00 strike. The total cost received by the writing party (or parties) was $31.0K, with a price of $155.0 per contract. There were 0 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
• For NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we notice a call option trade that happens to be bearish, expiring in 86 day(s) on September 20, 2024. This event was a transfer of 20 contract(s) at a $120.00 strike. The total cost received by the writing party (or parties) was $52.0K, with a price of $2600.0 per contract. There were 1105 open contracts at this strike prior to today, and today 7 contract(s) were bought and sold. 
• Regarding ALNY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>), we observe a put option trade with bearish sentiment. It expires in 86 day(s) on September 20, 2024. Parties traded 400 contract(s) at a $240.00 strike. The total cost received by the writing party (or parties) was $514.0K, with a price of $1285.0 per contract. There were 18 open contracts at this strike prior to today, and today 2 contract(s) were bought and sold. 
• Regarding STAA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>), we observe a call option sweep with bullish sentiment. It expires in 177 day(s) on December 20, 2024. Parties traded 20 contract(s) at a $30.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $32.6K, with a price of $1630.0 per contract. There were 33 open contracts at this strike prior to today, and today 0 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MRNA

RXRX

STAA

10 Health Care Stocks Whale Activity In Today's Session

Citigroup analyst David Lebovitz maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $227 to $291.

Citigroup Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $291

B of A Securities maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $248 to $295.

B of A Securities Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $295

Leerink Partners maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Market Perform and raises the price target from $138 to $159.

Leerink Partners Maintains Market Perform on Alnylam Pharmaceuticals, Raises Price Target to $159

TD Cowen analyst Ritu Baral maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $260 to $282.

TD Cowen Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $282

WIIM

Alnylam Pharmaceuticals are trading higher amid possible continued strength after the company yesterday announced topline results from its HELIOS-B Phase 3 study of vutrisiran. Also, multiple firms raised their respective price targets on the stock.

Evercore ISI Group analyst Liisa Bayko maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Outperform and raises the price target from $210 to $260.

Evercore ISI Group Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $260

Barclays analyst Gena Wang maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Overweight and raises the price target from $236 to $291.

Barclays Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $291

RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Outperform and raises the price target from $235 to $250.

RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $250

Wells Fargo analyst Tiago Fauth maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Equal-Weight and raises the price target from $161 to $207.

Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $207

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $400.00...

Buy Rating Affirmed for Alnylam Pharma: Promising Clinical Results and Strong Valuation

Sanofi a beneficiary of Alnylam's data on heart drug Amvuttra

Analyst Joseph Stringer of Needham maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), boosting the price target to $275.00. Joseph...

Strong Clinical Results Propel Alnylam Pharma's Buy Rating and Price Target Increase

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target of $28...

Alnylam Pharma (ALNY) Receives a Buy from TD Cowen

Alnylam Pharma (ALNY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tiago Fauth from ...

Maintaining Hold on Alnylam Pharma: Awaiting Full HELIOS-B Data to Confirm Vutrisiran Market Potential

Bank of America Securities analyst Tazeen Ahmad has reiterated their bullish stance on ALNY stock, giving a Buy rating today. Tazeen Ahmad's rating...

Upgraded Buy Rating on Alnylam Pharma with Increased Price Objective Following HELIOS-B Study Success

In a report released today, Luca Issi from RBC Capital maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target of $...

RBC Capital Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

RNAi: Winning In The Clinic, Now For The Market

Agilent Hit By Cyclical Headwinds, But The Growth Story Remains Intact Long Term

Alnylam, Lilly, AstraZeneca among best performing pharmas, biotechs in Q2

AMGN

BBIO

BRKR

GILD

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease

Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia

Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity

Alnylam Issues 2023 Corporate Responsibility Report

Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations

AbbVie

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BeiGene, Ltd. - American Depositary Shares

BeiGene

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Cerevel Therapeutics Holdings, Inc. - Common Stock

Cerevel Therapeutics Hldg

Exact Sciences Corporation - Common Stock

Exact Sciences

Gilead Sciences

Genmab

Incyte

Insmed

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

Vaxcyte

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

JP Morgan

Cantor Fitzgerald

RBC Capital

Stifel

6월은 <a href="https://www.benzinga.com/etfs" target="_blank" rel="noopener" data-google-interstitial="false">섹터 및 산업 성과</a>의 상당한 격차에도 불구하고 SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)가 추적하는 S&amp;P 500이 3.2% 상승하는 등 주식 시장에서 높은 평가를 받으며 마감되었다.
Technology Select Sector SPDR Fund(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)가 추적하는 기술 부문은 지난달 실적에서 11개 S&amp;P 500 섹터를 주도하며 7.7% 급등해 올해 가장 높은 월간 상승률을 달성했다.
이와는 대조적으로 유틸리티 부문은 Utilities Select Sector SPDR Fund(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)가 6.3% 하락해 2023년 9월 이후 최악의 달을 기록하는 등 부진했다.
<h3 class="wp-block-heading">6월 최고의 성과를 보인 산업 ETF들</h3>
iShares Expanded Tech-Software Sector ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGV#NYSE">IGV</a>)는 지난달 11.3% 상승하여 산업 ETF 중 1위를 차지했다.
이에 뒤이어 VanEck Semiconductor ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NYSE">SMH</a>)가 8.4% 상승하며 반도체 부문에서 강력한 모멘텀을 보여주었다.
VanEck Semiconductor ETF는 2023년 10월 최저치를 기록한 이후 무려 87%, 2022년 10월 이후로는 200% 이상 상승해 AI 중심 주식의 눈부신 성장을 반영했다.
월간 실적 측면에서 3위를 차지한 SPDR S&amp;P Biotech ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XBI#NYSE">XBI</a>)는 4% 상승했다.
소프트웨어 부문에서는 24.9% 상승한 어도비(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>), 22.1% 오른 크라우드스트라이크 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>), 20% 상승한 오라클(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>)이 눈에 띄는 성과를 거두었다.
브로드컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)는 21% 상승으로 칩 제조업체를 이끌었다. 유니버설 디스플레이 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLED#NYSE">OLED</a>)은 19.7% 증가로 그 뒤를 쫓았고, 코보(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>)는 18% 상승을 기록했다.
생명공학 분야에서 실렉스 홀딩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCLX#NASDAQ">SCLX</a>)는 78.8%의 급등을 경험하여 업계 최고의 상승세를 보였다. 앨라일람 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>)는 63.7% 급등한 반면, 어비디티 바이오사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>)는 52%의 강력한 상승세를 보였다.
<h3 class="wp-block-heading">6월 자금 유입량 상위 산업 ETF</h3>
자금 흐름을 조사한 결과 VanEck Semiconductor ETF는 투자자들에게 최고의 선택으로 부상했으며 트레이딩뷰(Tradingview) 데이터에 따르면 10억 달러 이상을 유치하고 9개월 연속 유입을 달성했다. 올해 현재까지 이 펀드는 46억 달러의 순유입을 기록했다.
iShares Expanded Tech-Software Sector ETF는 6월에 약 4억 8천만 달러를 유치하여 6개월 연속 유출을 깨고 2022년 9월 이후 가장 높은 월간 유입을 기록했다. 그러나 연간 순 흐름은 여전히 ​​11억 5천만 달러 마이너스이다.
iShares Biotechnology ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBB#NYSE">IBB</a>)는 투자자들의 높은 관심을 반영하여 지난달 1억 4,800만 달러의 자금을 유입했다. 강력한 유입을 목격한 또 다른 업계는 약 1억 3천만 달러를 유치한 Global X Copper Miners ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COPX#NYSE">COPX</a>)로 대표된다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39577080/manufacturing-contracts-more-than-expected-in-june-putting-pressure-on-profitabilit">6월 제조업 계약 예상보다 많아 &#8216;수익성 압박&#8217;: 수익률 상승, 주식 하락</a></li>
</ul>
사진: 셔터스톡

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>리비안 오토모티브(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>)는 회사가 생산량을 단순화하고 비용을 절감했으며 <a href="https://www.benzinga.com//node/39497161" target="_blank" rel="noreferrer noopener">폭스바겐과의 합작</a> 투자 계획을 발표했다는 보도가 나온 후 지난주 주가가 30.04% 급등했다.</li>
<li>카니발(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUK#NYSE">CUK</a>)의 주식은 <a href="https://www.benzinga.com//node/39481992" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">2분기 실적이 예상을 상회하는 결과</a>가 나타나자 17.78% 상승했다.</li>
<li>페덱스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>)의 주식은 예상보다 나은 4분기 재무 결과와 지침으로 인해 지난주 17.51% 급등했다. 또한 이 회사는 FY25에 <a href="https://www.benzinga.com//node/39504381" target="_blank" rel="noreferrer noopener">25억 달러</a> 상당의 주식을 다시 매입할 것이라고 발표했다. 몇몇 분석가들은 주식에 대한 <a href="https://www.benzinga.com//node/39509568" target="_blank" rel="noreferrer noopener">목표</a> 가격 예측을 높였다.</li>
<li>삼사라(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>)의 주식은 RBC 캐피털(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJ#NYSE">RJ</a>)가 <a href="https://www.benzinga.com/quote/iot/analyst-ratings" target="_blank" rel="noreferrer noopener">47달러의</a> 목표 주가를 유지하고 아웃퍼폼(Outperform) 평가를 재확정함에 따라 16.37% 상승했다.</li>
<li>수자노(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUZ#NYSE">SUZ</a>)의 주식은 인터내셔널 페이퍼(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IP#NYSE">IP</a>)의 인수 추진을 <a href="https://www.benzinga.com//node/39519611" target="_blank" rel="noreferrer noopener">중단했다는 소식</a> 이후 12.24% 치솟았다.</li>
<li>카바나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>)의 주식은 지난 <a href="https://www.benzinga.com//node/39509401" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">6월 초</a> 윌리엄 블레어(William Blair) 제 44회 연론회에서 자체 운영 계획과 자본 구조에 대한 업데이트 이후 11.93% 상승했다.</li>
<li>FTAI 에비에이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>)의 주식은 지난주 11.55% 상승했다.</li>
<li>레딧(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NASDAQ">RDDT</a>)의 주식은 <a href="https://www.benzinga.com//node/39494776" target="_blank" rel="noreferrer noopener">자동화된 웹 스크래핑을 차단하기 위한</a> 정책 업데이트를 발표한 후 11.08% 급등했다.</li>
<li>몽고DB(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>)의 주식은 지난주 10.57% 상승했다.</li>
<li>앨라일람 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>)의 주식은 회사가 부트리시란(vutrisiran)에 대한 HELIOS-B 3상 연구의 최고 결과를 발표한 후 지속적인 강세가 예상되는 가운데 주가는 10.82% 상승했다. 또한, 다수의 분석가들은 주식에 대한 전망 가격을 <a href="https://www.benzinga.com/quote/alny/analyst-ratings" target="_blank" rel="noreferrer noopener">상향 조정</a>했다.</li>
</ol>
다음 내용 읽기:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/06/39565694/moderna-and-walgreens-boots-alliance-were-among-the-10-biggest-large-cap-losers-last-week-june-23-">모더나와 월그린스 부츠는 지난주 최악의 성과를 보인 10대 대형주 중 일부 (6월 23일-6월 29일)</a></li>
</ul>
리비안의 사진

월요일 미국 주요 지수들은 혼조세를 보였다. 다우존스 산업평균지수는 0.7% 가까이 오른 39,411.21에 마감했고, S&amp;P 500 지수는 0.3% 하락한 5,447.87에 마감했다. 나스닥 지수는 1.1% 가까이 하락한 17,496.82로 마감했다.
이들은 하루 동안 소매 거래자와 투자자들의 주목을 받은 주요 종목들이다:
엔비디(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
엔비디아의 주식은 6.68% 하락하여 118.11달러에 마감했다. 주식의 일일 최고가는 124.46달러, 최저가는 118.04달러이다. 이 주식의 52주 범위는 39.23달러에서 140.76달러 사이에 있다. 이 반도체 회사는 <a href="https://www.benzinga.com/markets/equities/24/06/39462808/semiconductor-nvidia-woes-deepen-nasdaq-100-slips-dow-rallies-bitcoin-sinks-to-60-400-whats-driv">대규모 매도</a> 후 조정 영역에 진입했으며 CEO인 젠슨 황은 1억 달러 이상의 주식을 매도했다.
어펌 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>)
어펌의 주식은 12.82% 상승, 33.70달러에 마감했다. 이 주식의 일일 최고가는 34.13달러, 최저가는 30.77달러이다. 이 주식의 52주 범위는 12.81달러에서 52.48달러 사이에 있다. 골드만삭스의 분석가 윌 낸스(Will Nance)가 어펌을 매수 등급과 42달러 목표 가격으로 평가한 후 <a href="https://www.benzinga.com/news/24/06/39464043/whats-going-on-with-affirm-stock">주가가 상승</a>했다.
카니발 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>)
카니발의 주식은 1.99% 상승, 16.39달러에 마감했다. 이 주식의 일일 최고가는 16.5달러, 최저가는 16달러이다. 이 주식의 52주 범위는 10.84달러에서 19.74달러 사이에 있다. 이 회사는 화요일에 <a href="https://www.benzinga.com/general/entertainment/24/06/39464753/carnival-stock-in-strong-bullish-trend-ahead-of-q2-earnings-why-analyst-sees-multiyear-port" target="_blank" rel="noopener" data-google-interstitial="false">2분기 실적</a>을 보고할 예정이며, 월스트리트는 EPS가 마이너스 20센트, 매출이 57억 달러에 이를 것으로 예상하고 있다.
앨라일람 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>)
앨라일의 주식은 34.52% 급등해 222.90달러에 마감했다. 이 주식의 일일 최고가는 231.64달러, 최저가는 209.23달러이다. 이 주식의 52주 범위는 141.98달러에서 231.64달러 사이에 있다. 이 회사가 심근병증을 동반한 ATTR 아밀로이드증(ATTR-CM)에 대해 개발 중인 연구용 RNAi 치료제인 부트리시란(vutrisiran)에 대한 HELIOS-B 3상 연구에서 <a href="https://www.benzinga.com/general/biotech/24/06/39456940/alnylams-closely-watched-phase-3-heart-disease-trial-of-vutrisiran-hits-primary-endpoint-shares-s">긍정적인 결과</a>를 공개한 후 주가가 상승했다.
테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
테슬라의 주식은 0.23%의 소폭 하락, 182.58달러에 마감했다. 이 주식의 일일 최고가는 188.8달러, 최저가는 182.55달러이다. 이 주식의 52주 범위는 138.8달러에서 299.29달러 사이에 있다. 게리 블랙(Gary Black)은 테슬라에서 일론 머스크의 560억 달러 급여 패키지에 이의를 제기한 &#8216;토네타 대 머스크(Tornetta vs. Musk)&#8217; 사건에서 델라웨어 판사의 사법 활동주의를 <a href="https://www.benzinga.com/news/24/06/39449373/tesla-bull-gary-black-slams-delaware-chancellors-judicial-activism-in-elon-musks-56b-pay-package-cas" target="_blank" rel="noopener" data-google-interstitial="false">비판</a>하여 사법 역할과 입법 대응에 대한 광범위한 논쟁으로 이어졌다.
Jirapong Manustrong의 셔터스톡에서 사진
Benzinga의 최상의 <a href="Premarket Movers &amp; News">프리마켓 움직임과 뉴스</a>를 준비하십시오
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>에서 제작되었습니다. 그리고 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noopener noreferrer">Shivdeep Dhaliwal</a>에 의해 수정되었습니다.

Alnylam Pharmaceuticals

뉴스

에 대한 최신 뉴스 Alnylam Pharmaceuticals (NASDAQ:ALNY) 주식

화요일, 7월 02, 2024

일요일, 6월 30, 2024

화요일, 6월 25, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌